Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
Coronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10–17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21–28 days apart. To assess vaccine safety, 36,808 p...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/10/1765 |
| _version_ | 1797469620627570688 |
|---|---|
| author | Saraiorn Thonginnetra Kriangkrai Tawinprai Krongkwan Niemsorn Pathariya Promsena Manunya Tandhansakul Naruporn Kasemlawan Natthanan Ruangkijpaisal Narin Banomyong Nanthida Phattraprayoon Pisuttikan Rangkakulnuwat Preeda Vanichsetakul Teerapat Ungtrakul Kasiruck Wittayasak Nawarat Thonwirak Kamonwan Soonklang Nithi Mahanonda |
| author_facet | Saraiorn Thonginnetra Kriangkrai Tawinprai Krongkwan Niemsorn Pathariya Promsena Manunya Tandhansakul Naruporn Kasemlawan Natthanan Ruangkijpaisal Narin Banomyong Nanthida Phattraprayoon Pisuttikan Rangkakulnuwat Preeda Vanichsetakul Teerapat Ungtrakul Kasiruck Wittayasak Nawarat Thonwirak Kamonwan Soonklang Nithi Mahanonda |
| author_sort | Saraiorn Thonginnetra |
| collection | DOAJ |
| description | Coronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10–17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21–28 days apart. To assess vaccine safety, 36,808 participants were then followed with paper- and web-based online questionnaire surveys that captured local and systemic reactogenicities following vaccine administration on days 1, 7, and 30. Among participants, 76% (27,880) reported reactogenicity within the first 24 h and 7 days following the first dose. Half (51.41%) of participants experienced pain at the injection site; the majority of cases were mild in severity. Injection site tenderness (37.93%) was another common local reaction. Fatigue (37.89%), myalgia (33.56%), and headache (26.76%) were the most common systemic reactions. On days 2–7 after the first dose, 25.85% of participants experienced adverse reactions. Following the second dose, reactogenicity was 7.6% and 1.09% within 24 h and between days 2–7. The majority of reactions were of mild to moderate severity. We report that two doses of the BBIBP-CorV caused mild to moderate side effects in adolescents in Thailand. The findings confirm the vaccine’s safety profile in this age group. |
| first_indexed | 2024-03-09T19:23:50Z |
| format | Article |
| id | doaj.art-44c1de25d69f49a59a567ba112fa1cae |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T19:23:50Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-44c1de25d69f49a59a567ba112fa1cae2023-11-24T03:05:42ZengMDPI AGVaccines2076-393X2022-10-011010176510.3390/vaccines10101765Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in ThailandSaraiorn Thonginnetra0Kriangkrai Tawinprai1Krongkwan Niemsorn2Pathariya Promsena3Manunya Tandhansakul4Naruporn Kasemlawan5Natthanan Ruangkijpaisal6Narin Banomyong7Nanthida Phattraprayoon8Pisuttikan Rangkakulnuwat9Preeda Vanichsetakul10Teerapat Ungtrakul11Kasiruck Wittayasak12Nawarat Thonwirak13Kamonwan Soonklang14Nithi Mahanonda15Department of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandPrincess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Pediatrics, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandPrincess Srisavangavadhana College of Medicine, Chulabhorn Royal Academy, Bangkok 10210, ThailandChulabhorn Learning and Research Centre, Chulabhorn Royal Academy, Bangkok 10210, ThailandChulabhorn Learning and Research Centre, Chulabhorn Royal Academy, Bangkok 10210, ThailandChulabhorn Learning and Research Centre, Chulabhorn Royal Academy, Bangkok 10210, ThailandDepartment of Medicine, Chulabhorn Hospital, Chulabhorn Royal Academy, Bangkok 10210, ThailandCoronavirus disease 2019 affected child health and impacted learning because of the resulting onsite school closures. This prospective cohort study included children aged 10–17 who received two 4 µg doses of BBIBP-CorV administered intramuscularly 21–28 days apart. To assess vaccine safety, 36,808 participants were then followed with paper- and web-based online questionnaire surveys that captured local and systemic reactogenicities following vaccine administration on days 1, 7, and 30. Among participants, 76% (27,880) reported reactogenicity within the first 24 h and 7 days following the first dose. Half (51.41%) of participants experienced pain at the injection site; the majority of cases were mild in severity. Injection site tenderness (37.93%) was another common local reaction. Fatigue (37.89%), myalgia (33.56%), and headache (26.76%) were the most common systemic reactions. On days 2–7 after the first dose, 25.85% of participants experienced adverse reactions. Following the second dose, reactogenicity was 7.6% and 1.09% within 24 h and between days 2–7. The majority of reactions were of mild to moderate severity. We report that two doses of the BBIBP-CorV caused mild to moderate side effects in adolescents in Thailand. The findings confirm the vaccine’s safety profile in this age group.https://www.mdpi.com/2076-393X/10/10/1765COVID-19SARS-CoV-2BBIBP-CorVvaccinationimmunizationsafety |
| spellingShingle | Saraiorn Thonginnetra Kriangkrai Tawinprai Krongkwan Niemsorn Pathariya Promsena Manunya Tandhansakul Naruporn Kasemlawan Natthanan Ruangkijpaisal Narin Banomyong Nanthida Phattraprayoon Pisuttikan Rangkakulnuwat Preeda Vanichsetakul Teerapat Ungtrakul Kasiruck Wittayasak Nawarat Thonwirak Kamonwan Soonklang Nithi Mahanonda Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand Vaccines COVID-19 SARS-CoV-2 BBIBP-CorV vaccination immunization safety |
| title | Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand |
| title_full | Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand |
| title_fullStr | Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand |
| title_full_unstemmed | Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand |
| title_short | Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand |
| title_sort | safety after bbibp corv sinopharm covid 19 vaccine in adolescents aged 10 17 years in thailand |
| topic | COVID-19 SARS-CoV-2 BBIBP-CorV vaccination immunization safety |
| url | https://www.mdpi.com/2076-393X/10/10/1765 |
| work_keys_str_mv | AT saraiornthonginnetra safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT kriangkraitawinprai safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT krongkwanniemsorn safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT pathariyapromsena safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT manunyatandhansakul safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT narupornkasemlawan safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT natthananruangkijpaisal safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT narinbanomyong safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT nanthidaphattraprayoon safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT pisuttikanrangkakulnuwat safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT preedavanichsetakul safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT teerapatungtrakul safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT kasiruckwittayasak safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT nawaratthonwirak safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT kamonwansoonklang safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand AT nithimahanonda safetyafterbbibpcorvsinopharmcovid19vaccineinadolescentsaged1017yearsinthailand |